Steady progress over four decades toward understanding the pathogenesis and clinical
consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet …

Macrophages are a highly heterogeneous and plastic population of cells that are crucial for
tissue repair and regeneration. This has made macrophages a particularly attractive target …

Paclitaxel (PTX) is a widely used chemotherapeutic drug particularly effective against lung,
breast, and ovarian cancer, though its usefulness is limited due to its multi-organ toxicity …

Liver cirrhosis is one of the most prevalent chronic liver diseases worldwide. In addition to
viral hepatitis, diseases such as steatohepatitis, autoimmune hepatitis, sclerosing …

Hepatic fibrosis is a chronic liver disease that lacks effective pharmacotherapeutic
treatments. As part of the disease's mechanism, hepatic stellate cells (HSCs) are activated …

Background Diclofenac (DF) is a non-steroidal anti-inflammatory drug (NSAID) generally
prescribed for the treatment of pain. In spite of the widespread use of DF, hepatotoxicity has …

Liver fibrosis is the common consequence of various chronic liver injuries and is mainly
characterized by the imbalance between the production and degradation of extracellular …

Chronic inflammation is the hallmark of fibrotic disorders and is characterized by the
activation of immune cells in the damaged tissues. Macrophages have emerged as central …

Hepatic fibrosis is a dynamic process that occurs as a wound healing response against liver
injury. During fibrosis, crosstalk between parenchymal and non-parenchymal cells …

The incidence of hepatocellular carcinoma (HCC) and HCC-related deaths has increased
over the last few decades. There are several risk factors of HCC such as viral hepatitis (B …